Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Samuel S. Herrod"'
Publikováno v:
Multiple Sclerosis and Related Disorders. 30:176-186
Oral cladribine is a novel treatment for relapsing multiple sclerosis (MS). This appears to be a semi-selective immune-reconstitution therapy that induces long-term therapy from short treatment cycles. It has a relatively good safety profile that cur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41fb3d9549e309b98fb403f749b97907
https://doi.org/10.1016/j.msard.2019.02.018
https://doi.org/10.1016/j.msard.2019.02.018
Publikováno v:
JAMA neurology. 74(8)
Importance Alemtuzumab, a CD52-depleting monoclonal antibody, effectively inhibits relapsing multiple sclerosis (MS) but is associated with a high incidence of secondary B-cell autoimmunities that limit use. These effects may be avoided through contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc55453484bc9adc8b72ce9e0963a0d3
https://pubmed.ncbi.nlm.nih.gov/28604941
https://pubmed.ncbi.nlm.nih.gov/28604941
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 88:A52.1-A52
Background The use of alemtuzumab in people with relapsing MS (pwRMS) is limited by the high risk of secondary B cell autoimmunity (SAI). Data describing the effect of alemtuzumab on lymphocyte subsets collected during the phase III trials has never
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff6781bc93c43ac41f6ce66e626ceae1
https://doi.org/10.1136/jnnp-2017-abn.178
https://doi.org/10.1136/jnnp-2017-abn.178
Autor:
Lukasz Zalewski, Klaus Schmierer, David Baker, Christo Albor, Samuel S. Herrod, Cesar Alvarez-Gonzalez
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation
Objective:To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies.Methods:The regulatory sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::870873c868c067aeb7acc1d3dc0e58a1
https://doi.org/10.1212/nxi.0000000000000360
https://doi.org/10.1212/nxi.0000000000000360
Publikováno v:
Clinical Medicine. Sep2022, Vol. 22 Issue 5, p482-484. 3p.
Autor:
Baker, David, Herrod, Samuel S., Alvarez-Gonzalez, Cesar, Giovannoni, Gavin, Schmierer, Klaus
Publikováno v:
JAMA Neurology; Aug2017, Vol. 74 Issue 8, p961-969, 9p
Autor:
Baker, David, Herrod, Samuel S., Alvarez-Gonzalez, Cesar, Zalewski, Lukasz, Albor, Christo, Schmierer, Klaus
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation; Jul2017, Vol. 4 Issue 4, p1-10, 10p